期刊文献+

Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels 被引量:24

Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels
原文传递
导出
摘要 Background Increasing evidences indicate that an activated renin-angiotensin system (RAS) causes an imbalance between the vasoconstrictive and vasodilator mechanisms involving the pulmonary circulation leading to the development of pulmonary arterial hypertension (PAH). Angiotensin-converting enzyme 2 (ACE2), a primary component of the vasoprotective axis in RAS, is recently identified that it has regulatory actions in lung pathophysiology, but the mechanism in these processes is uncertain yet. Methods Severe PAH was induced by monocrotaline injection one week following pneumonectomy in rats. The activation of ACE2 by continuous injection of resorcinolnaphthalein was studied by real time-polymerase chain reaction (RT-PCR), Western blotting and fluorogenic peptide assay. Endothelial functions were evaluated by the response to acetylcholine and cytokines were measured by RT-PCR seven days after monocrotaline injection. The PAH-related hemodynamics and pathological changes were examined at day 21 when severe PAH was completely established. Results Resorcinolnaphthalein caused significant activation of ACE2 in both normal and diseased rats in 7 days after treatment. The pulmonary arterial pressure (PAP) started to increase at least 7 days after monocrotaline injection, and the rats developed severe PAH in 21 days with high PAP, right ventricular hypertrophy and neointimal formation. Treatment with resorcinolnaphthalein prevented these features. Resorcinolnaphthalein caused an improved endothelia-dependent vasorelaxation and decrease in proinflammatory cytokines (tumor necrosis factor (TNF)-a, monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6) and increase in anti-inflammatory cytokine IL-10 in the early stage of the pathogenesis. Conclusions These results demonstrated that activation of ACE2 by continuous injection of resorcinolnaphthalein prevented the development of PAH through improving early endothelial dysfunction and mediating the level of proinflammatory and anti-inflammatory cytokines. Background Increasing evidences indicate that an activated renin-angiotensin system (RAS) causes an imbalance between the vasoconstrictive and vasodilator mechanisms involving the pulmonary circulation leading to the development of pulmonary arterial hypertension (PAH). Angiotensin-converting enzyme 2 (ACE2), a primary component of the vasoprotective axis in RAS, is recently identified that it has regulatory actions in lung pathophysiology, but the mechanism in these processes is uncertain yet. Methods Severe PAH was induced by monocrotaline injection one week following pneumonectomy in rats. The activation of ACE2 by continuous injection of resorcinolnaphthalein was studied by real time-polymerase chain reaction (RT-PCR), Western blotting and fluorogenic peptide assay. Endothelial functions were evaluated by the response to acetylcholine and cytokines were measured by RT-PCR seven days after monocrotaline injection. The PAH-related hemodynamics and pathological changes were examined at day 21 when severe PAH was completely established. Results Resorcinolnaphthalein caused significant activation of ACE2 in both normal and diseased rats in 7 days after treatment. The pulmonary arterial pressure (PAP) started to increase at least 7 days after monocrotaline injection, and the rats developed severe PAH in 21 days with high PAP, right ventricular hypertrophy and neointimal formation. Treatment with resorcinolnaphthalein prevented these features. Resorcinolnaphthalein caused an improved endothelia-dependent vasorelaxation and decrease in proinflammatory cytokines (tumor necrosis factor (TNF)-a, monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6) and increase in anti-inflammatory cytokine IL-10 in the early stage of the pathogenesis. Conclusions These results demonstrated that activation of ACE2 by continuous injection of resorcinolnaphthalein prevented the development of PAH through improving early endothelial dysfunction and mediating the level of proinflammatory and anti-inflammatory cytokines.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第8期1381-1388,共8页 中华医学杂志(英文版)
基金 This study was supported by grants from the National Natural Science Foundation of China (No. 30972958), the Natural Science Foundation of Beijing (No. 7112046) and the Capital Characteristics Clinical Application Project (No. Z101107050210020)
关键词 pulmonary hypertension angiotensin-converting enzyme 2 ENDOTHELIUM INFLAMMATION pulmonary hypertension angiotensin-converting enzyme 2 endothelium inflammation
  • 相关文献

参考文献35

  • 1Barst RJ,McGoon M,Torbicki A,Sitbon O Krowka MJ Olschewski H. Diagnosis and differential assessment of pulmonary arterial hypertension[J].Journal of the American College of Cardiology,2004,(12 Suppl):40S-47S.
  • 2Archer SL,Weir EK,Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians:new concepts and experimental therapies[J].Circulation,2010.2045-2066.
  • 3Iwai M,Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin Ⅱ-AT1 receptor axis vs.ACE2-angiotensin-(1-7)-Mas receptor axis[J].Hypertension Research,2009.533-536.
  • 4Shenoy V,Qi Y,Katovich MJ,Raizada MK. ACE2,a promising therapeutic target for pulmonary hypertension[J].Current Opinion in Pharmacology,2011.150-155.
  • 5Bradford CN,Ely DR,Raizada MK. Targeting the vasoprotective axis of the renin-angiotensin system:a novel strategic approach to pulmonary hypertensive therapy[J].Current Hypertension Reports,2010.212-219.
  • 6Hyman AL,Hao Q,Tower A,Kadowitz PJ,Champion HC,Gumusel B. Novel catheterization technique for the in vivo measurement of pulmonary vascular responses in rats[J].American Journal of Physiology,1998,(4 Pt,2):H1218-HH229.
  • 7Nishimura T,Vaszar LT,Faul JL,Zhao G Berry GJ Shi L. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells[J].Circulation,2003,(13):1640-1645.doi:10.1161/01.CIR.0000087592.47401.37.
  • 8Noble JE,Bailey MJ. Quantitation of protein[J].Methods in Enzymology,2009.73-95.
  • 9Vickers C,Hales P,Kaushik V,Dick L Gavin J Tang J. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase[J].Journal of Biological Chemistry,2002.14838-14843.doi:10.1074/jbc.M200581200.
  • 10Oudit GY,Crackower MA,Backx PH,Penninger JM. The role of ACE2 in cardiovascular physiology[J].Trends in Cardiovascular Medicine,2003.93-101.doi:10.1016/S1050-1738(02)00233-5.

同被引文献63

引证文献24

二级引证文献118

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部